Poseida Therapeutics Current Valuation vs. Revenue

PSTX Stock  USD 9.50  0.01  0.11%   
Based on Poseida Therapeutics' profitability indicators, Poseida Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Poseida Therapeutics' ability to earn profits and add value for shareholders. Sales General And Administrative To Revenue is likely to rise to 0.97 in 2024, whereas Price To Sales Ratio is likely to drop 4.45 in 2024. At this time, Poseida Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 112.3 K in 2024, whereas Net Loss is likely to drop (60.5 M) in 2024.
For Poseida Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Poseida Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Poseida Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Poseida Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Poseida Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Poseida Therapeutics. If investors know Poseida will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Poseida Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.63)
Revenue Per Share
1.564
Quarterly Revenue Growth
6.672
Return On Assets
(0.13)
Return On Equity
(0.58)
The market value of Poseida Therapeutics is measured differently than its book value, which is the value of Poseida that is recorded on the company's balance sheet. Investors also form their own opinion of Poseida Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Poseida Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Poseida Therapeutics' market value can be influenced by many factors that don't directly affect Poseida Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Poseida Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Poseida Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Poseida Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Poseida Therapeutics Revenue vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Poseida Therapeutics's current stock value. Our valuation model uses many indicators to compare Poseida Therapeutics value to that of its competitors to determine the firm's financial worth.
Poseida Therapeutics is regarded fifth in current valuation category among its peers. It is rated top company in revenue category among its peers totaling about  0.08  of Revenue per Current Valuation. The ratio of Current Valuation to Revenue for Poseida Therapeutics is roughly  12.04 . At this time, Poseida Therapeutics' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Poseida Therapeutics' earnings, one of the primary drivers of an investment's value.

Poseida Current Valuation vs. Competition

Poseida Therapeutics is regarded fifth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 21.57 Billion. Poseida Therapeutics holds roughly 778.78 Million in current valuation claiming about 4% of equities under Health Care industry.

Poseida Revenue vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Poseida Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
778.78 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Poseida Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
64.7 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Poseida Revenue vs Competition

Poseida Therapeutics is rated top company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 116 Million. Poseida Therapeutics totals roughly 64.7 Million in revenue claiming about 56% of equities under Health Care industry.

Poseida Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Poseida Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Poseida Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Poseida Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Poseida Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income126 K132.3 K
Net Loss-57.6 M-60.5 M
Income Tax Expense107 K112.3 K
Net Interest Income-8.7 M-8.2 M
Operating Income-129.5 M-123 M
Net Loss-123.4 M-129.6 M
Income Before Tax-123.3 M-117.2 M
Total Other Income Expense Net6.2 M6.5 M
Net Loss-123.4 M-129.6 M
Non Operating Income Net Other3.3 M3.1 M
Change To Netincome22.2 M23.3 M
Net Loss(1.37)(1.44)
Income Quality 0.75  1.07 
Net Income Per E B T 1.00  1.05 

Poseida Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Poseida Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Poseida Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Poseida Therapeutics' important profitability drivers and their relationship over time.

Use Poseida Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Poseida Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Poseida Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Poseida Therapeutics Pair Trading

Poseida Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Poseida Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Poseida Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Poseida Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Poseida Therapeutics to buy it.
The correlation of Poseida Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Poseida Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Poseida Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Poseida Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Poseida Therapeutics position

In addition to having Poseida Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Retail Thematic Idea Now

Retail
Retail Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Retail theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Retail Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.